Total Payments
$290,935
2024 Payments
$87,261
Companies
29
Transactions
157
Payment Breakdown by Category
Consulting$212,607 (73.1%)
Other$61,957 (21.3%)
Travel$12,441 (4.3%)
Food & Beverage$2,795 (1.0%)
Research$1,125 (0.4%)
Education$10.51 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $212,607 | 81 | 73.1% |
| Acquisitions | $42,768 | 1 | 14.7% |
| Travel and Lodging | $12,441 | 33 | 4.3% |
| Honoraria | $10,500 | 2 | 3.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,689 | 3 | 3.0% |
| Food and Beverage | $2,795 | 35 | 1.0% |
| Unspecified | $1,125 | 1 | 0.4% |
| Education | $10.51 | 1 | 0.0% |
Payments by Type
General
$289,810
156 transactions
Research
$1,125
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $98,420 | 44 | $0 (2024) |
| Incyte Corporation | $42,768 | 1 | $0 (2024) |
| Merck Sharp & Dohme LLC | $27,030 | 19 | $0 (2024) |
| Novo Nordisk Inc | $24,567 | 7 | $0 (2024) |
| Gilead Sciences, Inc. | $18,427 | 14 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,304 | 12 | $0 (2024) |
| Janssen Research & Development, LLC | $8,197 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $7,752 | 10 | $0 (2020) |
| Lexicon Pharmaceuticals, Inc. | $7,214 | 2 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $6,808 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,261 | 28 | Incyte Corporation ($42,768) |
| 2023 | $21,060 | 13 | PFIZER INC. ($18,269) |
| 2022 | $31,421 | 19 | PFIZER INC. ($25,875) |
| 2021 | $39,928 | 17 | Novo Nordisk Inc ($16,498) |
| 2020 | $31,739 | 10 | PFIZER INC. ($12,618) |
| 2019 | $22,851 | 19 | Gilead Sciences, Inc. ($10,068) |
| 2018 | $17,677 | 17 | Lexicon Pharmaceuticals, Inc. ($7,214) |
| 2017 | $38,998 | 34 | PFIZER INC. ($8,610) |
All Payment Transactions
157 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $288.22 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.95 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $45.90 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $45.90 | General |
| 11/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.16 | General |
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $12,750.00 | General |
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $140.00 | General |
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,100.00 | General |
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $166.25 | General |
| 09/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $93.10 | General |
| 09/24/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 09/16/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,712.50 | General |
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $363.24 | General |
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $286.20 | General |
| 05/30/2024 | Incyte Corporation | — | Acquisitions | Cash or cash equivalent | $42,767.77 | General |
| 05/13/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| 04/29/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 03/26/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,410.00 | General |
| 03/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 03/11/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $265.92 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $64.99 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.98 | General |
| Category: IMMUNOLOGY | ||||||
| 03/04/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| HEPATIC IMPAIRMENT | Takeda Pharmaceuticals U.S.A., Inc. | $1,125 | 1 |
About Dr. Scott Friedman, MD
Dr. Scott Friedman, MD is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184656209.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Friedman, MD has received a total of $290,935 in payments from pharmaceutical and medical device companies, with $87,261 received in 2024. These payments were reported across 157 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($212,607).
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 07/07/2006
- Last Updated 03/17/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1184656209
Products in Payments
- Repatha (Biological) $2,616
- XIFAXAN (Drug) $2,500
- IDOR-1117-2520 $1,620
- Non-Covered Product (Drug) $600.00
- OCALIVA (Drug) $393.19
- INVOKANA (Drug) $168.00
- EGRIFTA (Drug) $18.22
- CC-90001 (Drug) $10.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554